Compare Charles Schwab Corporation Common Stock (SCHW) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles Schwab Corporation Common Stock vs State Street SPDR S&P Biotech ETF — how do they compare? Charles Schwab Corporation Common Stock trades at $106.54 (market cap $184.24B), while State Street SPDR S&P Biotech ETF trades at $159.85. The key difference: Charles Schwab Corporation Common Stock pays a 1.2% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Charles Schwab Corporation Common Stock nearer its low. Which is the better fit depends on your goals.
| SCHW | XBI | |
|---|---|---|
Market Cap | $184.24B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $113.65 | $169.55 |
52-Week Low | $85.35 | $93.43 |
Dividend Yield | 1.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles Schwab (SCHW) trades at $106.87, down 2.21% with a bearish technical signal. The stock shows strong fundamentals with Q2 2026 EPS beating expectations at $1.62 vs. $1.56 expected, continuing a trend of earnings beats. Revenue grew to $23.92B in 2025 with a robust 38.79% net income margin. Analyst consensus is bullish with 57% buy ratings and a $122.14 price target, representing 14% upside potential.
SCHW presents a compelling investment case with strong earnings momentum and expanding digital asset offerings, though near-term technical weakness and competitive pressures in the RIA custody space warrant caution. The company's diversified revenue streams and improving cash flow trends support long-term growth prospects despite current market volatility.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
